LOUISVILLE, Ky. (November 12, 2026) — As the 2027 open enrollment period gets underway, Guardant Health, Inc., a trusted leader in blood-based cancer tests for more than 10 years, is working with healthcare providers throughout Kentucky to expand access to its Shield™ blood test, the leading blood test for colorectal cancer detection and first to be approved by the FDA as a primary screening option for average-risk individuals age 45 and older.
This open enrollment period, running from November 1, 2026 through January 15, 2027, marks the first time majority of Americans covered by private insurance will have access to blood-based cancer screening tests.
Kentucky residents selecting or updating their plans are covered for the Shield blood test through their private insurer, with major insurers, including UnitedHealth Group and Carelon Services, confirming coverage this past summer. Most eligible adults covered by private insurance and Medicare enrollees will pay $0 out of pocket for the test.
Colorectal cancer is now the leading cause of cancer-related deaths among adults younger than 50. Kentucky is ranked second in the nation for colorectal cancer incidence rates. Despite this, more than 54 million Americans are currently behind on their recommended colorectal cancer screenings.
As residents review their healthcare coverage during open enrollment, access to innovative screening options like Shield offers a new opportunity to prioritize preventive care and early detection.
The Shield test is intended for individuals at average risk for colorectal cancer, age 45 or older.
For eligible patients in Kentucky, it is offered by prescription through a doctor or other healthcare professional and can be completed during a routine visit. For complete product information about the Shield blood test, including full safety information, visit Shieldbloodtest.com.
About Shield
Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
###

